Serveur d'exploration sur l'opéra

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

OP0223 M-ficolin, an activator of the complement system, predicts DAS28 remission in early DMARD naïve rheumatoid arthritis

Identifieur interne : 000637 ( Main/Exploration ); précédent : 000636; suivant : 000638

OP0223 M-ficolin, an activator of the complement system, predicts DAS28 remission in early DMARD naïve rheumatoid arthritis

Auteurs : C. G. Ammitzb Ll ; J. C. Jensenius ; T. Ellingsen ; S. Thiel ; K. H Rslev-Petersen ; M. Hetland ; P. Junker ; J. Johansen ; M. Stergaard ; J. P Denphant [Danemark] ; K. Stengaard-Pedersen

Source :

RBID : ISTEX:3B9E2DAA9E3DC5A3AF9DA0F22453DE8EA715735B

Abstract

Background M-ficolin is a soluble pattern recognition molecule that activates the complement system. We recently reported a factor 300 difference in the synovial fluid M-ficolin concentration between rheumatoid arthritis (RA) and osteoarthritis, suggesting a pathogenic role of M-ficolin1. Objectives To assess M-ficolin in DMARD naïve early RA patients, investigate correlations between M-ficolin and disease activity markers, and analyze the predictive value of M-ficolin. Methods 180 DMARD naïve RA patients with disease duration <6 months were included in a randomized double blind placebo-controlled trial (OPERA) of methotrexate, intraarticular glucucorticoids + either adalimumab (ADA) or placebo (PLA). A sandwich-type time-resolved immunofluorometric assay using monoclonal antibodies was used for quantification of M-ficolin in the OPERA cohort, 101 healthy adults and 51 chronic RA patients in remission. Concentrations are reported as medians. Spearman test, Students T-test and one-way analysis of variance were used. Logistic regression analyses were performed and adjusted for CRP, treatment group (ADA/PLA), x-ray erosions, anti-CCP, IgM-RF, neutrophils and monocytes. Results The highest M-ficolin levels were measured in the OPERA cohort at baseline (2.84μg/l, CI 2.63-3.09), and during treatment the level decreased 24% (CI 18-31%, p<0.001) at year one (2.31μg/l, CI 2.14-2.50). The healthy adults had significantly lower concentrations (1.88μg/l, CI 1.72-2.06) than the OPERA cohort at baseline (p<0.001) and year one (p<0.001), and the chronic RA patients (2.17μg/l, CI 1.94-2.42) (p=0.03). At baseline M-ficolin correlated to DAS28 (rho=0.29, p<0.001) and the four variables constituting DAS28 (0.001< p≤0.04). At year one M-ficolin correlated to DAS28 (rho=0.36, p<0.001) and 3 of the 4 variables constituting DAS28 (0.001< p≤0.05), except tender joint count 28 (p=0.23). Furthermore M-ficolin correlated to HAQ at debut (rho=0.25, p=0.003) and year one (rho=0.23, p<0.001). Logistic regression analysis determined M-ficolin as the strongest predictor of DAS28<2.6 at year one (coefficient=1.42, p=0.0001) followed by treatment group (PLA/ADA) (coefficient=1.23, p=0.001) and erosions on baseline x-ray (coefficient=-1.19, p=0.02), but M-ficolin was the only variable that predicted DAS28<3.2 at year one (coefficient=0.89, p=0.02). Low baseline M-ficolin level was the only variable associated with low disease activity at year one, and this was further analyzed by comparing the group with the 25% lowest baseline M-ficolin levels with the remaining 75% of patients (cutoff 2.00 μg/l). This resulted in a sensitivity of 29%, a specificity of 96%, and a positive predictive value of 98% in determining a DAS28 score <3.2 at year one. Conclusions The elevated baseline M-ficolin levels in early RA correlated consistently to disease activity markers, most notably DAS28 and HAQ, thus reflecting essential parts of the disease activity. Low M-ficolin levels at baseline predicts a positive predictive value of 98% of a DAS28<3.2 after one year irrespective of treatment and well-known prognostic factors. References Ammitzbøll CG, et al. Rheumatol Int 2011. Disclosure of Interest None Declared

Url:
DOI: 10.1136/annrheumdis-2012-eular.1906


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">OP0223 M-ficolin, an activator of the complement system, predicts DAS28 remission in early DMARD naïve rheumatoid arthritis</title>
<author>
<name sortKey="Ammitzb Ll, C G" sort="Ammitzb Ll, C G" uniqKey="Ammitzb Ll C" first="C. G." last="Ammitzb Ll">C. G. Ammitzb Ll</name>
</author>
<author>
<name sortKey="Jensenius, J C" sort="Jensenius, J C" uniqKey="Jensenius J" first="J. C." last="Jensenius">J. C. Jensenius</name>
</author>
<author>
<name sortKey="Ellingsen, T" sort="Ellingsen, T" uniqKey="Ellingsen T" first="T." last="Ellingsen">T. Ellingsen</name>
</author>
<author>
<name sortKey="Thiel, S" sort="Thiel, S" uniqKey="Thiel S" first="S." last="Thiel">S. Thiel</name>
</author>
<author>
<name sortKey="H Rslev Petersen, K" sort="H Rslev Petersen, K" uniqKey="H Rslev Petersen K" first="K." last="H Rslev-Petersen">K. H Rslev-Petersen</name>
</author>
<author>
<name sortKey="Hetland, M" sort="Hetland, M" uniqKey="Hetland M" first="M." last="Hetland">M. Hetland</name>
</author>
<author>
<name sortKey="Junker, P" sort="Junker, P" uniqKey="Junker P" first="P." last="Junker">P. Junker</name>
</author>
<author>
<name sortKey="Johansen, J" sort="Johansen, J" uniqKey="Johansen J" first="J." last="Johansen">J. Johansen</name>
</author>
<author>
<name sortKey=" Stergaard, M" sort=" Stergaard, M" uniqKey=" Stergaard M" first="M." last=" Stergaard">M. Stergaard</name>
</author>
<author>
<name sortKey="P Denphant, J" sort="P Denphant, J" uniqKey="P Denphant J" first="J." last="P Denphant">J. P Denphant</name>
</author>
<author>
<name sortKey="Stengaard Pedersen, K" sort="Stengaard Pedersen, K" uniqKey="Stengaard Pedersen K" first="K." last="Stengaard-Pedersen">K. Stengaard-Pedersen</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3B9E2DAA9E3DC5A3AF9DA0F22453DE8EA715735B</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1136/annrheumdis-2012-eular.1906</idno>
<idno type="url">https://api.istex.fr/document/3B9E2DAA9E3DC5A3AF9DA0F22453DE8EA715735B/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000905</idno>
<idno type="wicri:Area/Istex/Curation">000905</idno>
<idno type="wicri:Area/Istex/Checkpoint">000017</idno>
<idno type="wicri:doubleKey">0003-4967:2013:Ammitzb Ll C:op:m:ficolin</idno>
<idno type="wicri:Area/Main/Merge">000630</idno>
<idno type="wicri:Area/Main/Curation">000637</idno>
<idno type="wicri:Area/Main/Exploration">000637</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">OP0223 M-ficolin, an activator of the complement system, predicts DAS28 remission in early DMARD naïve rheumatoid arthritis</title>
<author>
<name sortKey="Ammitzb Ll, C G" sort="Ammitzb Ll, C G" uniqKey="Ammitzb Ll C" first="C. G." last="Ammitzb Ll">C. G. Ammitzb Ll</name>
<affiliation>
<wicri:noCountry code="no comma">Aarhus University Hospital</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Jensenius, J C" sort="Jensenius, J C" uniqKey="Jensenius J" first="J. C." last="Jensenius">J. C. Jensenius</name>
<affiliation>
<wicri:noCountry code="subField">Aarhus</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Ellingsen, T" sort="Ellingsen, T" uniqKey="Ellingsen T" first="T." last="Ellingsen">T. Ellingsen</name>
<affiliation>
<wicri:noCountry code="subField">Silkeborg</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Thiel, S" sort="Thiel, S" uniqKey="Thiel S" first="S." last="Thiel">S. Thiel</name>
<affiliation>
<wicri:noCountry code="subField">Aarhus</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="H Rslev Petersen, K" sort="H Rslev Petersen, K" uniqKey="H Rslev Petersen K" first="K." last="H Rslev-Petersen">K. H Rslev-Petersen</name>
<affiliation>
<wicri:noCountry code="subField">Gråsten</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Hetland, M" sort="Hetland, M" uniqKey="Hetland M" first="M." last="Hetland">M. Hetland</name>
<affiliation>
<wicri:noCountry code="subField">Glostrup</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Junker, P" sort="Junker, P" uniqKey="Junker P" first="P." last="Junker">P. Junker</name>
<affiliation>
<wicri:noCountry code="subField">Odense</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Johansen, J" sort="Johansen, J" uniqKey="Johansen J" first="J." last="Johansen">J. Johansen</name>
<affiliation>
<wicri:noCountry code="subField">Glostrup</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey=" Stergaard, M" sort=" Stergaard, M" uniqKey=" Stergaard M" first="M." last=" Stergaard">M. Stergaard</name>
<affiliation>
<wicri:noCountry code="subField">Glostrup</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="P Denphant, J" sort="P Denphant, J" uniqKey="P Denphant J" first="J." last="P Denphant">J. P Denphant</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Gentofte Hospital, Gentofte</wicri:regionArea>
<wicri:noRegion>Gentofte</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Stengaard Pedersen, K" sort="Stengaard Pedersen, K" uniqKey="Stengaard Pedersen K" first="K." last="Stengaard-Pedersen">K. Stengaard-Pedersen</name>
<affiliation>
<wicri:noCountry code="no comma">Aarhus University Hospital</wicri:noCountry>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint>
<publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2013-06">2013-06</date>
<biblScope unit="volume">71</biblScope>
<biblScope unit="issue">Suppl 3</biblScope>
<biblScope unit="page" from="131">131</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
<idno type="istex">3B9E2DAA9E3DC5A3AF9DA0F22453DE8EA715735B</idno>
<idno type="DOI">10.1136/annrheumdis-2012-eular.1906</idno>
<idno type="href">annrheumdis-71-131-1.pdf</idno>
<idno type="ArticleID">annrheumdis-2012-eular.1906</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Background M-ficolin is a soluble pattern recognition molecule that activates the complement system. We recently reported a factor 300 difference in the synovial fluid M-ficolin concentration between rheumatoid arthritis (RA) and osteoarthritis, suggesting a pathogenic role of M-ficolin1. Objectives To assess M-ficolin in DMARD naïve early RA patients, investigate correlations between M-ficolin and disease activity markers, and analyze the predictive value of M-ficolin. Methods 180 DMARD naïve RA patients with disease duration <6 months were included in a randomized double blind placebo-controlled trial (OPERA) of methotrexate, intraarticular glucucorticoids + either adalimumab (ADA) or placebo (PLA). A sandwich-type time-resolved immunofluorometric assay using monoclonal antibodies was used for quantification of M-ficolin in the OPERA cohort, 101 healthy adults and 51 chronic RA patients in remission. Concentrations are reported as medians. Spearman test, Students T-test and one-way analysis of variance were used. Logistic regression analyses were performed and adjusted for CRP, treatment group (ADA/PLA), x-ray erosions, anti-CCP, IgM-RF, neutrophils and monocytes. Results The highest M-ficolin levels were measured in the OPERA cohort at baseline (2.84μg/l, CI 2.63-3.09), and during treatment the level decreased 24% (CI 18-31%, p<0.001) at year one (2.31μg/l, CI 2.14-2.50). The healthy adults had significantly lower concentrations (1.88μg/l, CI 1.72-2.06) than the OPERA cohort at baseline (p<0.001) and year one (p<0.001), and the chronic RA patients (2.17μg/l, CI 1.94-2.42) (p=0.03). At baseline M-ficolin correlated to DAS28 (rho=0.29, p<0.001) and the four variables constituting DAS28 (0.001< p≤0.04). At year one M-ficolin correlated to DAS28 (rho=0.36, p<0.001) and 3 of the 4 variables constituting DAS28 (0.001< p≤0.05), except tender joint count 28 (p=0.23). Furthermore M-ficolin correlated to HAQ at debut (rho=0.25, p=0.003) and year one (rho=0.23, p<0.001). Logistic regression analysis determined M-ficolin as the strongest predictor of DAS28<2.6 at year one (coefficient=1.42, p=0.0001) followed by treatment group (PLA/ADA) (coefficient=1.23, p=0.001) and erosions on baseline x-ray (coefficient=-1.19, p=0.02), but M-ficolin was the only variable that predicted DAS28<3.2 at year one (coefficient=0.89, p=0.02). Low baseline M-ficolin level was the only variable associated with low disease activity at year one, and this was further analyzed by comparing the group with the 25% lowest baseline M-ficolin levels with the remaining 75% of patients (cutoff 2.00 μg/l). This resulted in a sensitivity of 29%, a specificity of 96%, and a positive predictive value of 98% in determining a DAS28 score <3.2 at year one. Conclusions The elevated baseline M-ficolin levels in early RA correlated consistently to disease activity markers, most notably DAS28 and HAQ, thus reflecting essential parts of the disease activity. Low M-ficolin levels at baseline predicts a positive predictive value of 98% of a DAS28<3.2 after one year irrespective of treatment and well-known prognostic factors. References Ammitzbøll CG, et al. Rheumatol Int 2011. Disclosure of Interest None Declared</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Danemark</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey=" Stergaard, M" sort=" Stergaard, M" uniqKey=" Stergaard M" first="M." last=" Stergaard">M. Stergaard</name>
<name sortKey="Ammitzb Ll, C G" sort="Ammitzb Ll, C G" uniqKey="Ammitzb Ll C" first="C. G." last="Ammitzb Ll">C. G. Ammitzb Ll</name>
<name sortKey="Ellingsen, T" sort="Ellingsen, T" uniqKey="Ellingsen T" first="T." last="Ellingsen">T. Ellingsen</name>
<name sortKey="H Rslev Petersen, K" sort="H Rslev Petersen, K" uniqKey="H Rslev Petersen K" first="K." last="H Rslev-Petersen">K. H Rslev-Petersen</name>
<name sortKey="Hetland, M" sort="Hetland, M" uniqKey="Hetland M" first="M." last="Hetland">M. Hetland</name>
<name sortKey="Jensenius, J C" sort="Jensenius, J C" uniqKey="Jensenius J" first="J. C." last="Jensenius">J. C. Jensenius</name>
<name sortKey="Johansen, J" sort="Johansen, J" uniqKey="Johansen J" first="J." last="Johansen">J. Johansen</name>
<name sortKey="Junker, P" sort="Junker, P" uniqKey="Junker P" first="P." last="Junker">P. Junker</name>
<name sortKey="Stengaard Pedersen, K" sort="Stengaard Pedersen, K" uniqKey="Stengaard Pedersen K" first="K." last="Stengaard-Pedersen">K. Stengaard-Pedersen</name>
<name sortKey="Thiel, S" sort="Thiel, S" uniqKey="Thiel S" first="S." last="Thiel">S. Thiel</name>
</noCountry>
<country name="Danemark">
<noRegion>
<name sortKey="P Denphant, J" sort="P Denphant, J" uniqKey="P Denphant J" first="J." last="P Denphant">J. P Denphant</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000637 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000637 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:3B9E2DAA9E3DC5A3AF9DA0F22453DE8EA715735B
   |texte=   OP0223 M-ficolin, an activator of the complement system, predicts DAS28 remission in early DMARD naïve rheumatoid arthritis
}}

Wicri

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Jan 4 23:09:23 2024